About Achieve

Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Achieve is currently conducting the ORCA (Ongoing Research of Cytisinicline for Addiction) Program in the United States and announced completion of enrollment of the Phase 3 ORCA-2 trial evaluating the cessation efficacy and safety of cytisinicline in adult cigarette smokers in June 2021. Topline results are expected in the second quarter of 2022.

Achieve’s focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for over eight million people losing their lives annually worldwide.

CDC Smoking Infographic